Press Releases

Date	Title
May 25, 2023	Chimerix to Participate in Cancer Moonshot Brain Cancers Forum on Glioblastoma (GBM) and Diffuse Intrinsic Pontine Glioma (DIPG) at White House Forum Aim is to Share Progress and Spur Actions to Advance the Field DURHAM, N.C. , May 25, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, announced
May 04, 2023	Chimerix Reports First Quarter 2023 Financial Results and Provides Operational Update – European Union Study Authorization for Phase 3 ACTION Received, Reiterate First Efficacy Data Expected Early 2025 – – Completion of ONC206 Dose Escalation Expected by First Half 2024 – – Conference Call at 8:30 a.m. ET Today – DURHAM, N.C. , May 04, 2023 (GLOBE NEWSWIRE) --
Apr 27, 2023	Chimerix to Report First Quarter 2023 Financial Results and Provide an Operational Update on May 4, 2023 DURHAM, N.C. , April 27, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that it will host a live conference call and audio webcast
Apr 18, 2023	Chimerix Announces Presentation of Multiple Imipridone Datasets at American Association for Cancer Research Annual Meeting Key Presentation Highlights Ability of ONC201 to Reverse Epigenetic Signature of H3 K27M Mutation in Glioma Patients Multiple Preclinical Datasets Support Potential of Imipridone Platform DURHAM, N.C. , April 18, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose
Mar 02, 2023	Chimerix Reports Fourth Quarter and Year End 2022 Financial Results and Provides Operational Update - Continued Execution and Progress Towards Commercial Approval of Dordaviprone (ONC201) with Global Launch of Phase 3 ACTION Study – – Confirmed Response in Non-H3 K27M Recurrent Glioblastoma Patient During ONC206 Dose Escalation – – Strong Balance Sheet with $266 Million in Cash at Year-End and No
Feb 28, 2023	Chimerix to Present at Cowen and Company 43rd Annual Health Care Conference DURHAM, N.C. , Feb. 28, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Sherman , Chief Executive Officer, will participate
Feb 23, 2023	Chimerix to Report Fourth Quarter and Year End 2022 Financial Results and Provide an Operational Update on March 2, 2023 DURHAM, N.C. , Feb. 23, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that it will host a live conference call and audio webcast on
Jan 05, 2023	Chimerix to Present at 41st Annual J.P. Morgan Healthcare Conference DURHAM, N.C. , Jan. 05, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Sherman , Chief Executive Officer, will present a

Oncology